Dupilumab for Prevention of Recurrence of CRSwNP After ESS

NCT04596189 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Chronic Rhinosinusitis With Nasal Polyps

Interventions

DRUG: Dupilumab 300 MG in 2 ML Prefilled Syringe
OTHER: Placebo
DRUG: Mometasone Furoate nasal spray

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)